ANIK vs VCEL
ANIK: Anika Therapeutics is a regenerative medicine company specializing in hyaluronic acid-based solutions for joint health and soft tissue repair. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | ANIK | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $19.28 | $45.32 | |
| Market cap as of 2026-08-03 | $258M | $2.3B | |
| P/E as of 2026-08-03 | n/a | 109.36 | |
| PEG as of 2026-08-03 | n/a | 0.38 | |
| Net margin as of 2026-08-03 | -9.5% | +7.3% | VCEL higher |
| Gross margin as of 2026-08-03 | +58.6% | +74.8% | VCEL higher |
| Operating margin as of 2026-08-03 | -10.5% | +5.4% | VCEL higher |
| ROE as of 2026-08-03 | -7.7% | +6.4% | VCEL higher |
| ROA as of 2026-08-03 | -5.9% | +4.6% | VCEL higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.00 | ANIK lower |
| Revenue growth (YoY) as of 2026-08-03 | -15.4% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +18.9% | VCEL higher |
| Beta as of 2026-08-03 | 0.90 | 1.07 | |
| 1-year return as of 2026-07-31 close | +133.4% | +13.0% | ANIK higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.